The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system and thus improving the lives of millions of patients worldwide.
EDITOR OF THE MONTH
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital.
Read More
Read More
EDITOR OF THE MONTH
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital.
Editor of the month
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital, Clichy, France.
PROF. DR. SVEN FRANCQUE
LATEST ARTICLES
NASH: bariatric surgery and major adverse liver and cardiovascular outcomes
In this retrospective cohort study of 1158 patients with biopsy-proven fibrotic NASH without cirrhosis, bariatric surgery was significantly associated with a lower risk of major adverse liver outcomes.
Latest Videos
Latest articles from PubMed
- Neonatal Oral Administration of Chrysin Prevents Long-Term Development of Non-Alcoholic Fatty Liver Disease in a Sexually Dimorphic Manner in Fructose Nurtured Sprague Dawley Rats
- The Role of Macronutrients in the Pathogenesis, Prevention and Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Paediatric Population-A Review
- Distinct Cytokine Profiles in Severe COVID-19 and Non-Alcoholic Fatty Liver Disease
- Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease
- Exploring the Path of Mediterranean Diet, Non-Alcoholic Fatty Liver Disease (NAFLD) and Inflammation towards 10-Year Cardiovascular Disease (CVD) Risk: The ATTICA Study 10-Year Follow-Up (2002-2012)
- Associations of Sex Steroids and Sex Hormone-Binding Globulin with Non-Alcoholic Fatty Liver Disease: A Population-Based Study and Meta-Analysis
- Kinsenoside alleviates inflammation and fibrosis in experimental NASH mice by suppressing the NF-κB/NLRP3 signaling pathway
- Letter: association of circulating bile acid concentrations and non-alcoholic fatty liver disease-authors' reply
sign up for our newsletter
The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system, thus improving the lives of millions of patients worldwide.
Subscribe to us and get new updates